Innovation will continue to drive the pharma and biotech sectors in 2015 as forecasts point to another prosperous year according to EP Vantage’s report, Pharma & Biotech 2015 Preview, based on EvaluatePharma data.
Key highlights include:
A dozen products due to be launched next year are forecast to achieve blockbuster sales by 2020
Drugs treating high cholesterol and heart failure will dominate the field with a combined 2020 sales forecast of $8 billion
Sovaldi and its combination product Harvoni will take the number one worldwide seller spot with forecasted sales of $15.3 billion in 2015
Patent expiries will have minimal impact on the top line as 2015 sales will grow close to four times that of patent losses
Financing climate appears friendly and deals will continue at a steady pace but M&A activity unlikely to match the frenzy of 2014.
To download this report, please confirm your details on the form opposite.
Download your copy of the report: